Lena Behrmann
Dr.
Lena Behrmann
  • 1.Arbeitsbereich
Sprachen
Deutsch (Muttersprache)
Englisch

Tätigkeitsschwerpunkte

Publikationen

2024

Murine Regulatory CD4+ T Cells Are Increased in Leukemic Spleens and Show High Co-Expression of Co-Regulatory Molecules CD39, CD73, PD1, and TIGIT
Krüger J, Wellbrock J, Witt M, Kruppa N, Muschhammer J, Bokemeyer C, Modemann F, Fiedler W, Behrmann L, Brauneck F
INT J MOL SCI. 2024;25(21):.

Pediatric T-cell lymphoblastic lymphomas but not leukemias harbor TRB::NOTCH1 fusions with unfavorable outcome
Te Vrugt M, Wessolowski J, Randau G, Alfert A, Mueller S, Scholten K, Sopalla C, Lanvers-Kaminsky C, Hotfilder M, Lamp F, Damm-Welk C, Luedersen J, Escherich G, Zur Stadt U, Behrmann L, Woessmann W, Oschlies I, Marzi M, Zimmermann M, Burkhardt B
BLOOD. 2024;144(13):1412-1417.

2021

The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia
Wellbrock J, Behrmann L, Muschhammer J, Modemann F, Khoury K, Brauneck F, Bokemeyer C, Campeau E, Fiedler W
ANN HEMATOL. 2021;100(12):2933-2941.

2020

The bone marrow stromal niche: a therapeutic target of hematological myeloid malignancies
Behrmann L, Wellbrock J, Fiedler W
EXPERT OPIN THER TAR. 2020;24(5):451-462.

Downregulation of GLI3 Expression Mediates Chemotherapy Resistance in Acute Myeloid Leukemia
Freisleben F, Behrmann L, Thaden V, Muschhammer J, Bokemeyer C, Fiedler W, Wellbrock J
INT J MOL SCI. 2020;21(14):.

2018

Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look
Behrmann L, Wellbrock J, Fiedler W
FRONT ONCOL. 2018;8:444.

Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL
Siekmann I, Dierck K, Prall S, Klokow M, Strauss J, Buhs S, Wrzeszcz A, Bockmayr M, Beck F, Trochimiuk M, Gottschling K, Martens V, Khosh-Naucke M, Gerull H, Müller J, Behrmann L, Blohm M, Zahedi R, Jeremias I, Sickmann A, Nollau P, Horstmann M
BLOOD ADV. 2018;2(19):2554-2567.

Letzte Aktualisierung aus dem FIS: 23.12.2024 - 23:34 Uhr